115195
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
信迪利单抗所致免疫检查点抑制剂相关肠狭窄：病例报告
Authors Li HY, Liu Y, Hu SL, Li YQ, Tang TY
Received 21 August 2025
Accepted for publication 26 December 2025
Published 10 January 2026 Volume 2026:19 556800
DOI https://doi.org/10.2147/JIR.S556800
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Alberto Caminero
Hong Yan Li, Yue Liu, Si Leng Hu, Yu Qin Li, Tong Yu Tang
Gastroenterology Department, The First Hospital of Jilin University, Changchun, Jilin, People’s Republic of China
Correspondence: Yu Qin Li, Gastroenterology Department, The First Hospital of Jilin University, Changchun, Jilin, People’s Republic of China, Email liyuq@jlu.edu.cn Tong Yu Tang, Gastroenterology Department, The First Hospital of Jilin University, Changchun, Jilin, People’s Republic of China, Email tangty@jlu.edu.cn
Abstract: Immune checkpoint inhibitors (ICIs) as an immunotherapy have significantly prolonged the overall survival (OS) and progression-free survival (PFS) of patients with various advanced cancers, and have significantly increased the objective response rate. However, excessive activation of the immune system may attack normal organs, triggering a series of immune-related adverse reactions. Among them, due to the relatively high incidence of immune-mediated colitis (IMC), it is particularly worthy of attention. Xindili Antibody is a fully human immunoglobulin G4 monoclonal antibody that targets the programmed cell death receptor 1 (PD-1) pathway. It is of great significance in cancer immunotherapy and has shown good anti-tumor effects in various malignant tumors. Here, we report a case of a 64-year-old male with colorectal cancer and lung metastasis. After using Sintilimab, the patient developed inflammatory intestinal obstruction. The colonic stenosis caused by immune checkpoint inhibitors may be the result of the combined effects of chronic immune inflammation, microbial flora imbalance, and disrupted tissue repair. This case report emphasizes the importance of early identification and appropriate intervention to prevent the permanent interruption of immune checkpoint inhibitor treatment and the prevention of colitis complications.
Keywords: immune checkpoint inhibitors, colitis, anti-PD-1, immune-mediated colitis, Sintilimab
Gastroenterology Department, The First Hospital of Jilin University, Changchun, Jilin, People’s Republic of China
Correspondence: Yu Qin Li, Gastroenterology Department, The First Hospital of Jilin University, Changchun, Jilin, People’s Republic of China, Email liyuq@jlu.edu.cn Tong Yu Tang, Gastroenterology Department, The First Hospital of Jilin University, Changchun, Jilin, People’s Republic of China, Email tangty@jlu.edu.cn
Abstract: Immune checkpoint inhibitors (ICIs) as an immunotherapy have significantly prolonged the overall survival (OS) and progression-free survival (PFS) of patients with various advanced cancers, and have significantly increased the objective response rate. However, excessive activation of the immune system may attack normal organs, triggering a series of immune-related adverse reactions. Among them, due to the relatively high incidence of immune-mediated colitis (IMC), it is particularly worthy of attention. Xindili Antibody is a fully human immunoglobulin G4 monoclonal antibody that targets the programmed cell death receptor 1 (PD-1) pathway. It is of great significance in cancer immunotherapy and has shown good anti-tumor effects in various malignant tumors. Here, we report a case of a 64-year-old male with colorectal cancer and lung metastasis. After using Sintilimab, the patient developed inflammatory intestinal obstruction. The colonic stenosis caused by immune checkpoint inhibitors may be the result of the combined effects of chronic immune inflammation, microbial flora imbalance, and disrupted tissue repair. This case report emphasizes the importance of early identification and appropriate intervention to prevent the permanent interruption of immune checkpoint inhibitor treatment and the prevention of colitis complications.
Keywords: immune checkpoint inhibitors, colitis, anti-PD-1, immune-mediated colitis, Sintilimab